Rose discusses genetic testing for cancer with OncLive
In a recent installment of OncLiveTV, UW Ob-Gyn Division of Gynecologic Oncology Director Steve Rose, MD discussed the importance of genetic testing in ovarian cancer.
In the video, Rose mentioned the importance of genetic testing in setting a treatment path for some ovarian cancers:
“The importance of the testing, for sure, has to do with the use of PARP inhibitors, specifically now that PARP inhibitors up front have been shown to be helpful in certain patients. And so making sure that you can get that ball rolling quickly and start talking to patients about whether or not they’re going to be eligible, dependent upon their BRCA either somatic or genetic status, and homologous recombination proficient or deficient status as well,” Rose says.
Rose also discusses current barriers to genetic testing in ovarian cancer patients. Watch the whole video here!